T

TScan Therapeutics Inc
NASDAQ:TCRX

Watchlist Manager
TScan Therapeutics Inc
NASDAQ:TCRX
Watchlist
Price: 3.1375 USD 5.64%
Market Cap: 167.4m USD
Have any thoughts about
TScan Therapeutics Inc?
Write Note

TScan Therapeutics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TScan Therapeutics Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
T
TScan Therapeutics Inc
NASDAQ:TCRX
Interest Income Expense
$4.2m
CAGR 3-Years
238%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$598m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TScan Therapeutics Inc
Glance View

Market Cap
167.4m USD
Industry
Biotechnology

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The firm's platform technologies include TargetScan, ReceptorScan and T-Integrate.

TCRX Intrinsic Value
1.4104 USD
Overvaluation 55%
Intrinsic Value
Price
T

See Also

What is TScan Therapeutics Inc's Interest Income Expense?
Interest Income Expense
4.2m USD

Based on the financial report for Dec 31, 2023, TScan Therapeutics Inc's Interest Income Expense amounts to 4.2m USD.

What is TScan Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
238%

Over the last year, the Interest Income Expense growth was 910%. The average annual Interest Income Expense growth rates for TScan Therapeutics Inc have been 238% over the past three years .

Back to Top